Table 3.
Adjusted outcomes by AAD use at baseline
| Amiodarone vs. No AAD | Other AAD vs. No AAD | Amiodarone vs. Other AAD | ||||
|---|---|---|---|---|---|---|
| HR (95% CI) | P-Value | HR (95% CI) | P-Value | HR (95% CI) | P-Value | |
| Efficacy outcomes | ||||||
| All-cause death | 0.98 (0.74, 1.31) | 0.90 | 0.66 (0.37, 1.17) | 0.15 | 1.49 (0.78, 2.84) | 0.22 |
| Vascular death | 0.89 (0.61, 1.31) | 0.56 | 0.60 (0.27, 1.34) | 0.21 | 1.48 (0.61, 3.61) | 0.39 |
| Non-vascular death | 1.14 (0.76, 1.71) | 0.52 | 0.74 (0.32, 1.70) | 0.48 | 1.54 (0.62, 3.81) | 0.35 |
| Stroke or non-CNS embolism | 1.17 (0.76, 1.81) | 0.48 | 0.57 (0.26, 1.22) | 0.15 | 2.06 (0.87, 4.90) | 0.10 |
| Stroke, non-CNS embolism, MI, or vascular death | 1.06 (0.80, 1.39) | 0.69 | 0.79 (0.49, 1.26) | 0.32 | 1.34 (0.78, 2.32) | 0.29 |
| Stroke | 1.03 (0.67, 1.57) | 0.90 | 0.59 (0.26, 1.31) | 0.20 | 1.75 (0.73, 4.21) | 0.21 |
| Non-CNS embolism | 2.34 (0.83, 6.59) | 0.11 | 0.56 (0.08, 3.90) | 0.55 | 4.21 (0.54, 32.5) | 0.17 |
| MI | 1.76 (1.11, 2.77) | 0.02 | 1.35 (0.63, 2.92) | 0.44 | 1.30 (0.53, 3.17) | 0.56 |
| Cardiac failure | 1.17 (0.95, 1.44) | 0.14 | 0.86 (0.52, 1.43) | 0.56 | 1.36 (0.79, 2.35) | 0.27 |
| Hospitalization | 1.13 (0.92, 1.39) | 0.25 | 1.06 (0.79, 1.41) | 0.70 | 1.06 (0.75, 1.49) | 0.75 |
| ED visit | 0.91 (0.78, 1.07) | 0.26 | 1.21 (0.96, 1.51) | 0.10 | 0.76 (0.58, 1.00) | 0.99 |
| Safety outcomes | ||||||
| Major or NMCR bleeding | 0.98 (0.81, 1.18) | 0.81 | 0.83 (0.63, 1.09) | 0.18 | 1.18 (0.85, 1.64) | 0.32 |
| Major bleeding | 0.90 (0.61, 1.31) | 0.58 | 0.77 (0.45, 1.32) | 0.34 | 1.17 (0.61, 2.23) | 0.64 |
| NMCR bleeding | 0.99 (0.80, 1.21) | 0.90 | 0.80 (0.59, 1.09) | 0.16 | 1.23 (0.86, 1.77) | 0.25 |
AAD=antiarrhythmic drug; CI=confidence interval; CNS=central nervous system; ED=emergency department; HR=hazard ratio; MI=myocardial infarction; NMCR=non-major clinically relevant.